Program
ivacaftor
Also written as “IVA”, “Ivacaftor” and “ELX/TEZ/IVA”.
Its studies are mostly in Cystic Fibrosis · Ciliary Motility Disorders, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 744 open or running | phase 4since Aug 15, 2016 | Apr 5, 2007 | Apr 6, 2027phase 3 · NCT05331183 |
| Sun Pharmaceutical Industries | 30 open or running | phase 1since Mar 5, 2015 | Mar 5, 2015 | none ahead |
| Parion Sciences | 10 open or running | phase 2since Aug 12, 2016 | Aug 12, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Oct 8, 2012.
- Aug 28, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04537793 · 83 enrolled · United States, Australia, Canada and more
- Sep 3, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04545515 · 120 enrolled · Australia, Canada, Denmark and more
- Oct 21, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04599465 · 69 enrolled · Australia, Belgium, Czechia and more
- Jul 9, 2021Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04969224 · 82 enrolled · Australia, Belgium, Canada and more
- Oct 27, 2021Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05111145 · 86 enrolled · Australia, Belgium, Canada and more
- Nov 29, 2021Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05153317 · 71 enrolled · United States, Australia, Canada and more
- Mar 1, 2022Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05274269 · 307 enrolled · Austria, Belgium, Canada and more
- Apr 8, 2022Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05331183 · 297 enrolled · Austria, Belgium, Canada and more
- May 19, 2023Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05882357 · 67 enrolled · Australia, Canada, Denmark and more
- Nov 23, 2023Phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT06154447 · 165 enrolled · United States
- Jun 10, 2024Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT06460506 · 50 enrolled · Australia, Canada, Denmark and more
- Dec 4, 2025Phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07283770 · 152 planned · United States
- Feb 20, 2026Phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07437105 · 160 planned · United States
- Oct 19, 2026Primary completion moved from 2026-11-19 to 2027-07-12Date moved laterphase 1 · +8 months · NCT07283770
Ahead
- Apr 6, 2027Primary completion: phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05331183
- Jun 26, 2027Primary completion: phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07437105
- Jul 12, 2027Primary completion: phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07283770
- Sep 30, 2027Primary completion: phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT06460506
TargetBeta
“Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator”ChEMBL 37, by rule
Other programs on CFTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lumacaftorrule | Vertex Pharmaceuticals | phase 4 | 23 |
| tezacaftorrule | Vertex Pharmaceuticals | phase 3 | 39 |
Studies
The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07437105Cystic Fibrosis · United States | 1 | Recruiting | Vertex Pharmaceuticals | Jun 26, 2027 | 160 |
| NCT07283770Cystic Fibrosis · United States | 1 | Recruiting | Vertex Pharmaceuticals | Jul 12, 2027 | 152 |
| NCT06460506Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Active, not recruiting | Vertex Pharmaceuticals | Sep 30, 2027 | 50 |
| NCT06154447Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | Jul 10, 2026 | 165 |
| NCT05882357Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Vertex Pharmaceuticals | Sep 4, 2025 | 67 |
| NCT05331183Cystic Fibrosis · Austria, Belgium, Canada and more | 3 | Active, not recruiting | Vertex Pharmaceuticals | Apr 6, 2027 | 297 |
| NCT05274269Cystic Fibrosis · Austria, Belgium, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Jul 5, 2023 | 307 |
| NCT05153317Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Jan 29, 2026 | 71 |
| NCT05111145Cystic Fibrosis · Australia, Belgium, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Dec 20, 2022 | 86 |
| NCT04969224Cystic Fibrosis · Australia, Belgium, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Jul 26, 2022 | 82 |
| NCT04599465Cystic Fibrosis · Australia, Belgium, Czechia and more | 3 | Completed | Vertex Pharmaceuticals | Jul 14, 2022 | 69 |
| NCT04545515Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Vertex Pharmaceuticals | Mar 24, 2023 | 120 |
| NCT04537793Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Jun 3, 2022 | 83 |
| NCT04362761Cystic Fibrosis · Australia, Belgium, Germany and more | 3 | Completed | Vertex Pharmaceuticals | Dec 21, 2022 | 172 |
| NCT04353817Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Vertex Pharmaceuticals | May 17, 2021 | 121 |
| NCT04235140Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Aug 22, 2023 | 52 |
| NCT04183790Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Feb 24, 2024 | 64 |
| NCT04058366Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Dec 16, 2022 | 251 |
| NCT03911713Cystic Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Vertex Pharmaceuticals | Aug 20, 2020 | 77 |
| NCT03768089Cystic Fibrosis · Netherlands, United Kingdom | 2 | Completed | Vertex Pharmaceuticals | May 3, 2019 | 115 |
| NCT03691779Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Aug 7, 2020 | 71 |
| NCT03625466Cystic Fibrosis · Germany | 2 | Completed | Vertex Pharmaceuticals | Oct 9, 2020 | 51 |
| NCT03633526Cystic Fibrosis · United States | 3 | Terminated | Vertex Pharmaceuticals | Jan 18, 2019 | 18 |
| NCT03601637Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Oct 29, 2021 | 61 |
| NCT03559062Cystic Fibrosis · Australia, Belgium, Denmark and more | 3 | Completed | Vertex Pharmaceuticals | Dec 21, 2018 | 67 |
| NCT03537651Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Oct 28, 2020 | 130 |
| NCT03486236Cystic Fibrosis · United Kingdom | 1 | Completed | Vertex Pharmaceuticals | Sep 14, 2016 | 16 |
| NCT03277196Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Oct 2, 2023 | 86 |
| NCT03224351Cystic Fibrosis · United States, Ireland, Israel and more | 2 | Completed | Vertex Pharmaceuticals | Feb 28, 2018 | 124 |
| NCT03150719Cystic Fibrosis · United States, France, Germany | 3 | Completed | Vertex Pharmaceuticals | Aug 9, 2018 | 98 |
| NCT03125395Cystic Fibrosis · United States, Canada | 3 | Completed | Vertex Pharmaceuticals | Jul 17, 2019 | 57 |
| NCT03068312Cystic Fibrosis · Israel | 3 | Completed | Vertex Pharmaceuticals | Dec 18, 2018 | 38 |
| NCT03061331Cystic Fibrosis · Netherlands | 2 | Completed | Vertex Pharmaceuticals | Sep 6, 2017 | 20 |
| NCT02971839Cystic Fibrosis · United States | 2 | Terminated | Vertex Pharmaceuticals | Aug 2017 | 11 |
| NCT02951195Cystic Fibrosis · United States | 2 | Completed | Vertex Pharmaceuticals | Jan 2018 | 80 |
| NCT02951182Cystic Fibrosis · United States, Australia, Austria and more | 2 | Completed | Vertex Pharmaceuticals | Aug 2017 | 74 |
| NCT02875366Cystic Fibrosis · Australia, United Kingdom | 4 | Completed | Vertex Pharmaceuticals | Sep 2017 | 70 |
| NCT02871778Ciliary Motility Disorders · United States, Canada, Denmark and more | 2 | Completed | Parion Sciences | Nov 20, 2018 | 123 |
| NCT02742519Cystic Fibrosis · Australia, Canada, United Kingdom | 3 | Terminated | Vertex Pharmaceuticals | Aug 2017 | 14 |
| NCT02730208Cystic Fibrosis · Australia | 2 | Completed | Vertex Pharmaceuticals | Jul 2018 | 41 |
| NCT02725567Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Jun 28, 2022 | 57 |
| NCT02680249Healthy · Australia | 1 | Completed | Sun Pharmaceutical Industries | Apr 2016 | 15 |
| NCT02599792Healthy · Australia | 1 | Completed | Sun Pharmaceutical Industries | Apr 2016 | 37 |
| NCT02565914Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | May 2019 | 1,131 |
| NCT02544451Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Aug 2018 | 246 |
| NCT02516410Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | Jun 7, 2016 | 168 |
| NCT02514473Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Sep 2016 | 206 |
| NCT02508207Cystic Fibrosis · United States | 2 | Completed | Vertex Pharmaceuticals | Jun 2017 | 34 |
| NCT02412111Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | Sep 2017 | 156 |
| NCT02392234Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Vertex Pharmaceuticals | Feb 2017 | 248 |
| NCT02392702Healthy · Australia | 1 | Completed | Sun Pharmaceutical Industries | Jun 2015 | 15 |
| NCT02347657Cystic Fibrosis · United States, Canada, Denmark and more | 3 | Completed | Vertex Pharmaceuticals | Jan 20, 2017 | 510 |
| NCT02015507Cystic Fibrosis | 1 | Completed | Vertex Pharmaceuticals | Feb 2014 | 34 |
| NCT01946412Cystic Fibrosis · United States, Canada, United Kingdom | 3 | Completed | Vertex Pharmaceuticals | Dec 2015 | 33 |
| NCT01931839Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2016 | 1,164 |
| NCT01807949Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2014 | 563 |
| NCT01807923Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2014 | 559 |
| NCT01768663Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | Sep 2013 | 80 |
| NCT01707290Cystic Fibrosis · United States, Belgium, France and more | 3 | Completed | Vertex Pharmaceuticals | Apr 2016 | 125 |
| NCT01705145Cystic Fibrosis · United States, Canada, United Kingdom | 3 | Completed | Vertex Pharmaceuticals | Mar 2014 | 35 |
How it is read
Names in the registry
- “IVA”, 26 entries
- “Ivacaftor”, 26 entries
- “ELX/TEZ/IVA”, 14 entries
- “VX-770”, 10 entries
- “LUM/IVA”, 8 entries
Codes read as this program: VX770.
Conditions, from the studies’ own filings
- Cystic Fibrosis, 74 studies
- Ciliary Motility Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.